Cochrane · systematic review · CD000209
Vitamin E for antipsychotic‐induced tardive dyskinesia
Soares‐Weiser, K, Maayan, N, Bergman, H · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 16.7%Very low 3 · 50%Low 2 · 33.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyVITAMIN E compared with PLACEBO for antipsychotic‐induced tardive dyskinesia
Population: patients with various chronic psychiatric disorders, but mainly schizophrenia, and antipsychotic‐induced tardive dyskinesia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tardive dyskinesia: 1. Not improved to a clinically important extent VITAMIN E vs PLACEBO | RR 0.95 [0.89, 1.01] | 6 studies · 264 participants | Low Downgraded: risk of bias, imprecision |
Tardive dyskinesia: 3. Deterioration of symptoms VITAMIN E vs PLACEBO | RR 0.23 [0.07, 0.76] | 5 studies · 85 participants | Low Downgraded: risk of bias, imprecision |
Adverse effect: any VITAMIN E vs PLACEBO | RR 1.21 [0.35, 4.15] | 9 studies · 205 participants | Very low Downgraded: imprecision |
Adverse effect: extrapyramidal symptoms measured by Simpson‐Angus Scale (low = better) VITAMIN E vs PLACEBO | no estimate extracted | 1 study · 104 participants | Very low Downgraded: risk of bias, imprecision |
Acceptability of treatment (measured by participants leaving the study early) VITAMIN E vs PLACEBO | RR 1.07 [0.64, 1.8] | 8 studies · 232 participants | Very low Downgraded: imprecision, indirectness |
Social confidence, social inclusion, social networks, or personalised quality of life VITAMIN E vs PLACEBO | no estimate extracted | 0 studies · 0 participants | Ungraded |
VITAMIN E compared with PLACEBO for neuroleptic‐induced tardive dyskinesia
Population: patients with neuroleptic‐induced tardive dyskinesia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tardive dyskinesia: 1. Not improved to a clinically important extent VITAMIN E vs PLACEBO | RR 0.96 [0.9, 1.02] | 6 studies · 256 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Tardive dyskinesia: 2. Not any improvement VITAMIN E vs PLACEBO | RR 0.86 [0.75, 1] | 7 studies · 311 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Tardive dyskinesia: 3. Deterioration of symptoms VITAMIN E vs PLACEBO | RR 0.38 [0.16, 0.9] | 5 studies · 98 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Adverse effect: any VITAMIN E vs PLACEBO | RR 1.29 [0.51, 3.24] | 9 studies · 203 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, publication bias |
Adverse effect: specific VITAMIN E vs PLACEBO | no estimate extracted | 0 studies · 0 participants | Ungraded |
Quality of life VITAMIN E vs PLACEBO | no estimate extracted | 0 studies · 0 participants | Ungraded |